All In Biotech

Drug Trial Radar · NCT06748079

A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of Single/Multiple Dose Escalation of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Dec 3, 2024

Primary completion

Aug 7, 2026

Study completion Aug 7, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation powder in Chronic Obstructive Pulmonary Disease(COPD) patients with single/multiple dose escalation.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TQC3721 inhalation powderDrug

    TQC3721 is a target inhibitor.

  • Placebo for TQC3721 inhalation powderDrug

    Placebo without drug substance.

  • TQC3721 inhalation powder combined with glyberlam inhalation powder or a control groupDrug

    TQC3721 is a target inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE)Time frame: 21 days
  2. Serious Adverse Events (SAE)Time frame: 21 days
  3. Treatment-emergent adverse events (TEAEs)Time frame: 19 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.